Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01028794

Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients

Phase 1/2A Study of Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Patients After Cerebral Embolism

Sponsor: Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan

Conditions Cerebral Embolism Stroke

Interventions autologous bone marrow mononuclear cells

Updated 6 times since 2017 Last updated: Jul 4, 2013 Started: May 31, 2008 Primary completion: Jul 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Cerebral Embolism and Stroke, this trial is completed. The trial is conducted by Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan and has accumulated 6 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Nov 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Nov 2023 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

May 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute of Biomedical Research and Innovation, Kobe, Hyogo, Japan
National Cerebral and Cardiovascular Center, Japan

Data source: National Cerebral and Cardiovascular Center, Japan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Suita, Japan